Developer site: The content shown here is test data.

Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Back to skin conditions

Pheochromocytoma laboratory findings

Introduction

Overview

Overview

Laboratory findings consistent with the diagnosis of pheochromocytoma include elevated 24-hour urinary fractionated catecholamines and metanephrines for low-risk patients and plasma fractionated metanephrines for high-risk patients.

Laboratory Findings

Laboratory Findings

An elevated concentration of the following is diagnostic of pheochromocytoma.

  • Elevated 24-hour urine fractionated metanephrines and catecholamines. The cutoff values are: [1]
  • Elevated plasma fractionated metanephrines. The cutoff values are:
    • Metanephrine > 0.3-0.5 nmol/L
    • Normetanephrine > 0.66- 0.9 nmol/L [2] [3]

The following drugs interfere with urinary catecholamines metabolism and shoudl be discontinued two weeks before any hormonal assessments: [5]

  • Tricyclic antidepressants (TCAs)
  • Levodopa
  • Antipsychotics
  • Ethanol
  • Acetaminophen
  • Phenoxybenzamine [6]

Patients with spells of elevated blood pressure (sudden onset of a symptom or symptoms) can be negative in-between spells and should be tested directly after the attacks.[7]

References

References

  1. ↑ Sawka AM, Jaeschke R, Singh RJ, Young WF (2003). “A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines”. J Clin Endocrinol Metab. 88 (2): 553–8. doi:10.1210/jc.2002-021251. PMID 12574179.
  2. ↑ 2.0 2.1 Lenders JW, Keiser HR, Goldstein DS, Willemsen JJ, Friberg P, Jacobs MC; et al. (1995). “Plasma metanephrines in the diagnosis of pheochromocytoma”. Ann Intern Med. 123 (2): 101–9. doi:10.7326/0003-4819-123-2-199507150-00004. PMID 7778821.
  3. ↑ Pattarino F, Bouloux PM (1996). “The diagnosis of malignancy in phaeochromocytoma”. Clin Endocrinol (Oxf). 44 (2): 239–41. doi:10.1046/j.1365-2265.1996.657475.x. PMID 8849581.
  4. ↑ Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P; et al. (2002). “Biochemical diagnosis of pheochromocytoma: which test is best?”. JAMA. 287 (11): 1427–34. PMID 11903030.
  5. ↑ Gimenez-Roqueplo AP, Lehnert H, Mannelli M, Neumann H, Opocher G, Maher ER; et al. (2006). “Phaeochromocytoma, new genes and screening strategies”. Clin Endocrinol (Oxf). 65 (6): 699–705. doi:10.1111/j.1365-2265.2006.02714.x. PMID 17121518.
  6. ↑ Kudva YC, Sawka AM, Young WF (2003). “Clinical review 164: The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience”. J Clin Endocrinol Metab. 88 (10): 4533–9. doi:10.1210/jc.2003-030720. PMID 14557417.
  7. ↑ Young WF, Maddox DE (1995). “Spells: in search of a cause”. Mayo Clin Proc. 70 (8): 757–65. PMID 7630214.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2] Mohammed Abdelwahed M.D[3]